Compare Capri Holdings Ltd (CPRI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs Sana Biotechnology Inc — how do they compare? Capri Holdings Ltd trades at $16.45 (market cap $1.91B), while Sana Biotechnology Inc trades at $3.58 (market cap $994.89M). The key difference: Capri Holdings Ltd is the larger of the two by market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| CPRI | SANA | |
|---|---|---|
Market Cap | $1.91B | $994.89M |
Sector | Consumer Staples | Health |
52-Week High | $27.66 | $5.92 |
52-Week Low | $16.68 | $2.68 |
Enterprise Value | $3.20B | $969.08M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $17.46, down 3.22% on the day, with a bearish technical signal from moving averages and oscillators neutral. The company reported a net loss of $1.18 billion in 2025 despite a gross profit margin of 62.26%. Recent news highlights a post-Versace turnaround focus on Michael Kors and Jimmy Choo, with management projecting fiscal 2027 growth. Analyst consensus is a buy rating with a $23.33 price target, implying significant upside from current levels.
The investment case hinges on successful execution of the two-brand strategy and return to profitability. Key risks include sustained luxury demand weakness and high debt levels, while potential rewards include valuation upside if earnings guidance is met. The stock presents a high-risk, high-reward opportunity contingent on operational improvements.
SANA Biotechnology trades at $3.64, down 5.45% over 24 hours, with a bullish technical signal and strong analyst support (81.82% buy ratings). Recent news highlights clinical progress, including NEJM publications and conference presentations, but financials show significant losses with a net income of -$244.17M in 2025 and negative cash flows.
The outlook is mixed: strong scientific momentum and Wall Street optimism contrast with deep financial losses and high burn rate. Key risks include funding needs and clinical trial outcomes, while potential upside hinges on successful product development and partnerships.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
